Yong Ben - Aug 11, 2025 Form 3 Insider Report for BridgeBio Oncology Therapeutics, Inc. (BBOT)

Role: Chief Med & Dev Officer
Signature: /s/ Aaron Chan, Attorney-in-Fact
Stock symbol: BBOT
Transactions as of: Aug 11, 2025
Transactions value $: $0
Form type: 3
Date filed: 8/18/2025, 05:11 PM
Previous filing: Jun 2, 2025
Next filing: Aug 28, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Ben Yong	Chief Med & Dev Officer	BRIDGEBIO ONCOLOGY THERAPEUTICS, INC., 256 EAST GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO	/s/ Aaron Chan, Attorney-in-Fact	2025-08-18	0001967669

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	BBOT	Stock Option (Right to Buy)							Aug 11, 2025	Common Stock	443K	$4.17	Direct	F1
holding	BBOT	Stock Option (Right to Buy)							Aug 11, 2025	Common Stock	26.6K	$7.88	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the shares underlying such option shall vest on September 3, 2025, with the remainder vesting in thirty-six substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service the Issuer on each such vesting date.
F2	1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 4, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Exhibit 24 - Power of Attorney